BRCA1 and metastatic prostate carcinoma: On the basis of the data from phase III trials, we can propose that germline and somatic testing in all individuals with metastatic prostate cancer is necessary to maximize the positive effects of the combination therapy of PARP inhibitors plus NHT, especially for those who harbor HRR gene alteration and BRCA1/2 mutation.